Fulgent Genetics (FLGT)
Combines hereditary-cancer and pathology testing with a nanoencapsulated cancer-drug pipeline in clinical trials.
Something off on this page? Send us feedback.
Runs a next-generation-sequencing laboratory network spanning hereditary-cancer, reproductive-health, oncology, and rare-disease testing, anatomic pathology built through a string of cash-funded acquisitions, and contract sequencing for biopharma customers, while a wholly owned subsidiary advances a nanoencapsulated chemotherapy platform through mid-stage and early-stage cancer trials.
Operates a next-generation-sequencing laboratory spanning hereditary-cancer, reproductive-health, oncology, and rare-disease testing; an anatomic-pathology practice covering gastrointestinal, dermatopathology, breast, and hematopathology cases assembled through acquisitions; and a contract-sequencing unit serving biopharmaceutical and academic customers.
A wholly owned subsidiary runs a separate track: a proprietary nanoencapsulation drug-delivery platform advancing a lead paclitaxel candidate through a mid-stage trial in recurrent head-and-neck cancer, alongside a second candidate in early-stage dose escalation.
Testing volume during the pandemic built a large cash reserve funding every pathology acquisition without new debt or share issuance. The founder, who also chairs the board, holds roughly a third of outstanding shares, and operations concentrate in the United States alongside a minority stake in a Chinese joint venture.
The largest customer in the hereditary- and oncology-testing business has begun moving its testing in-house, a transition still working through segment results.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Reiterate | Rating: —Target: $15 | Target: $19 |
| May 5, 2026 | Piper Sandler | Reiterate | Rating: —Target: $21 | Target: $15 |
| Nov 14, 2025 | Raymond James | Target | Target: $25 | Target: $36 |
| Aug 5, 2025 | UBS | Upgrade | Target: — | Target: $30 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $257.0M · Total debt $9.4M · Total assets $1.09B · Shareholders' equity $1.00B
- Revenue
- $85.4M
- Operating income
- −$33.9M
- Net income
- −$29.5M
No dividends on record.
| Institutions | 58.32% | 16.05M shares | |
|---|---|---|---|
| 147 holders · as of Jun 30, 2026 | |||
| Insiders | 9.74% | 2.68M shares | |
| 7 holders · as of Sep 3, 2026 | |||
| Strategic holders | 3.88% | 1.07M shares | |
| 1 holder · as of Jun 12, 2020 | |||
| Other | 28.06% | 7.72M shares | |
| remainder | |||
27.52M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.31% | 2.29M | as of Jun 30, 2026 |
Xi Long USA, Inc.1Strategic10 percent owner | 3.88% | 1.07M | filed Jun 12, 2020 |
Acadian Asset Management LLCInstitution | 3.70% | 1.02M | as of Jun 30, 2026 |
Hanlin GaoInsiderofficer: Chief Scientific Officer | 3.58% | 986,117 | filed Sep 3, 2026 |
Ming HsiehInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 3.22% | 885,952 | filed Sep 3, 2026 |
- Xi Long USA, Inc.'s own ownership statement (13G/A, Jun 12, 2020) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Jian Xie | officer: President and COO | −2,127 | $19.66 |
| Sep 2, 2026 | Hanlin Gao | officer: Chief Scientific Officer | −1,673 | $19.66 |
| Aug 27, 2026 | Hanlin Gao | officer: Chief Scientific Officer | −939 | $19.91 |
| Aug 27, 2026 | Jian Xie | officer: President and COO | −1,193 | $19.91 |
| May 27, 2026 | Hanlin Gao | officer: Chief Scientific Officer | −945 | $17.60 |
- NeoGenomics
Overlaps in oncology NGS, liquid biopsy, hereditary panels, and pathology
- Labcorp
Diversified clinical/genomic reference lab with anatomic pathology services
- Natera
Overlaps in reproductive health, hereditary cancer, and oncology liquid biopsy
- Guardant Health
Precision oncology liquid biopsy testing for cancer detection and screening
- Myriad Genetics
Molecular diagnostics for hereditary cancer risk and prenatal screening
- Castle Biosciences
Niche overlap in dermatopathology risk-stratification testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Fulgent Genetics | $21.65 | +0.52% | $611.7M | — | — | 1.9 | +4.4% |
| NeoGenomics | $19.07 | −1.74% | $498.7M | — | 68.6 | 0.7 | +11.2% |
| Labcorp | $313.01 | −2.49% | $26.32B | 26.6 | 16.5 | 1.8 | +5.8% |
| Natera | $386.55 | +4.29% | $53.08B | — | — | 19.6 | +37.7% |
| Guardant Health | $177.11 | +1.86% | $23.33B | — | — | 19.7 | +44.3% |
| Myriad Genetics | $3.93 | −2.12% | $378.7M | — | — | 0.5 | −10.5% |
| Castle Biosciences | $35.09 | +0.29% | $1.07B | — | — | 3.0 | +20.1% |
| Median | 26.6 | 42.6 | 2.4 | +15.7% |